Before moving to the next drugs, its worth mentioning exenatides subsequent formulations
In those cases, weight loss may not be appropriate, and a GLP-1 may not be the best first move
doi: 10.3389/ftox.2025.1687862 Received 03 September 2025 Revised 15 October 2025 Accepted 17 October 2025 Published 24 November 2025 Corrected 16 February 2025 Volume 7 - 2025 Edited by Ahmed Elsayed Noreldin, Damanhour University, Egypt Reviewed by Thomas Hofmann, Thomas Hofmann Toxicological Consulting (THC), Germany Juman Khaleel Al-Sabbagh, University of Kerbala, Iraq Updates Copyright 2025 Okon, Fasogbon, Swase, Dangana, Makena, Ojiakor, Etukudo, Chebet, Musyoka, Ifie, Mbyemeire, Mbina, Ugwu, Oviosun, Usman, Ifie, Rangasamy, Olorunnisola, Mounmbegna, Noreen and Aja
We suggest that combined treatment with agents that block the SNS could diminish the hypertensive effect of DPP-4i and that this effect may be enhanced by agents with no effect on the SNS
3) postinflammatory conditions, such as, lichen planus or smoker's melanosis1, 2, 5
mit dem Urin ber die Nieren ausgeschieden , um eine stabile Konzentration im Blut aufrechtzuerhalten